» Articles » PMID: 38547072

A Phage-displayed Disulfide Constrained Peptide Discovery Platform Yields Novel Human Plasma Protein Binders

Overview
Journal PLoS One
Date 2024 Mar 28
PMID 38547072
Authors
Affiliations
Soon will be listed here.
Abstract

Disulfide constrained peptides (DCPs) show great potential as templates for drug discovery. They are characterized by conserved cysteine residues that form intramolecular disulfide bonds. Taking advantage of phage display technology, we designed and generated twenty-six DCP phage libraries with enriched molecular diversity to enable the discovery of ligands against disease-causing proteins of interest. The libraries were designed based on five DCP scaffolds, namely Momordica charantia 1 (Mch1), gurmarin, Asteropsin-A, antimicrobial peptide-1 (AMP-1), and potato carboxypeptidase inhibitor (CPI). We also report optimized workflows for screening and producing synthetic and recombinant DCPs. Examples of novel DCP binders identified against various protein targets are presented, including human IgG Fc, serum albumin, vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor (PDGF). We identified DCPs against human IgG Fc and serum albumin with sub-micromolar affinity from primary panning campaigns, providing alternative tools for potential half-life extension of peptides and small protein therapeutics. Overall, the molecular diversity of the DCP scaffolds included in the designed libraries, coupled with their distinct biochemical and biophysical properties, enables efficient and robust identification of de novo binders to drug targets of therapeutic relevance.

Citing Articles

Bioproduction Platform to Generate Functionalized Disulfide-Constrained Peptide Analogues.

Hwang S, Balana A, Martin B, Clarkson M, Di Lello P, Wu H ACS Bio Med Chem Au. 2024; 4(4):190-203.

PMID: 39184057 PMC: 11342346. DOI: 10.1021/acsbiomedchemau.4c00026.


Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors.

Goodrich A, LeClair N, Shillova N, Morton W, Wittwer A, Loyet K J Biol Chem. 2024; 300(7):107467.

PMID: 38876307 PMC: 11283208. DOI: 10.1016/j.jbc.2024.107467.


Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform.

Zhou L, Cai F, Li Y, Gao X, Wei Y, Fedorova A PLoS One. 2024; 19(3):e0300135.

PMID: 38547109 PMC: 10977697. DOI: 10.1371/journal.pone.0300135.

References
1.
Jenssen H, Aspmo S . Serum stability of peptides. Methods Mol Biol. 2008; 494:177-86. DOI: 10.1007/978-1-59745-419-3_10. View

2.
Goransson U, Craik D . Disulfide mapping of the cyclotide kalata B1. Chemical proof of the cystic cystine knot motif. J Biol Chem. 2003; 278(48):48188-96. DOI: 10.1074/jbc.M308771200. View

3.
Williams J, Day M, Heavner J . Ziconotide: an update and review. Expert Opin Pharmacother. 2008; 9(9):1575-83. DOI: 10.1517/14656566.9.9.1575. View

4.
DeLano W, Ultsch M, de Vos A, Wells J . Convergent solutions to binding at a protein-protein interface. Science. 2000; 287(5456):1279-83. DOI: 10.1126/science.287.5456.1279. View

5.
Ostergaard S, Paulsson J, Kofoed J, Zosel F, Olsen J, Jeppesen C . The effect of fatty diacid acylation of human PYY on Y receptor potency and half-life in minipigs. Sci Rep. 2021; 11(1):21179. PMC: 8551270. DOI: 10.1038/s41598-021-00654-3. View